
Sign up to save your podcasts
Or


The non-vitamin-K oral anticoagulants (known familiarly as NOACs or DOACs) share metabolic pathways with other drugs, which can potentiate NOACs’ anticoagulant actions dangerously. Dr. Shang-Hung Chang and his group studied Taiwan’s national health insurance database, which records data on virtually all that nation’s citizens, to measure the actual risks of some of these drug – drug interactions. Their findings were published earlier this month in JAMA.
Links:
JAMA article (abstract)
Physician’s First Watch coverage
By NEJM Group4.5
5656 ratings
The non-vitamin-K oral anticoagulants (known familiarly as NOACs or DOACs) share metabolic pathways with other drugs, which can potentiate NOACs’ anticoagulant actions dangerously. Dr. Shang-Hung Chang and his group studied Taiwan’s national health insurance database, which records data on virtually all that nation’s citizens, to measure the actual risks of some of these drug – drug interactions. Their findings were published earlier this month in JAMA.
Links:
JAMA article (abstract)
Physician’s First Watch coverage

7,913 Listeners

321 Listeners

2,053 Listeners

124 Listeners

504 Listeners

299 Listeners

906 Listeners

264 Listeners

3,374 Listeners

113,121 Listeners

89 Listeners

5 Listeners

94 Listeners

518 Listeners

2,592 Listeners

367 Listeners

16,525 Listeners

59 Listeners

31 Listeners

63 Listeners